- Virios Therapeutics ( NASDAQ: VIRI ) said enrollment in an exploratory Long-COVID trial began and the first patient was dosed.
- The study is supported via an investigational grant to the Bateman Horne Center, the company noted in an Aug. 15 press release.
- The company said the study will evaluate antiviral therapy with Virios' second development combination, IMC-2 (valacyclovir + celecoxib), to treat the symptoms linked with Long-COVID, including fatigue, pain, sleep disruption, anxiety, depression and cognitive function.
For further details see:
Virios Therapeutics Long-COVID trial begins dosing